PLYX

Polaryx Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing treatments for patients with rare and underserved diseases. Headquartered in Woburn, Massachusetts, the company advances its lead product candidate, ADX-2191, a subcutaneously administered therapy designed to treat hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling. Polaryx originated from Aldeyra Therapeutics, which spun off its HAE program in 2024 to allow focused development of this distinct therapeutic area. The company's business model centers on advancing ADX-2191 through clinical trials and regulatory pathways, with a Phase 3 program evaluating the therapy's efficacy and safety in HAE patients. Polaryx operates within the competitive rare disease pharmaceutical sector, where several approved HAE treatments exist, but the company aims to differentiate its candidate through improved dosing convenience and administration profile. As a pre-revenue entity, the company relies on capital markets and strategic partnerships to fund its development activities. The HAE market represents a significant opportunity within orphan drug development, with affected patients requiring long-term prophylactic treatment to prevent debilitating attacks. Polaryx maintains a streamlined organizational structure typical of clinical-stage biotechnology companies, concentrating resources on clinical development, regulatory affairs, and operational execution.